Profiles of Volatile Biomarkers Detect Tuberculosis from Skin.


Journal

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569

Informations de publication

Date de publication:
08 2021
Historique:
revised: 19 03 2021
received: 20 01 2021
pubmed: 3 6 2021
medline: 18 1 2022
entrez: 2 6 2021
Statut: ppublish

Résumé

Tuberculosis (TB) is an infectious disease that threatens >10 million people annually. Despite advances in TB diagnostics, patients continue to receive an insufficient diagnosis as TB symptoms are not specific. Many existing biodiagnostic tests are slow, have low clinical performance, and can be unsuitable for resource-limited settings. According to the World Health Organization (WHO), a rapid, sputum-free, and cost-effective triage test for real-time detection of TB is urgently needed. This article reports on a new diagnostic pathway enabling a noninvasive, fast, and highly accurate way of detecting TB. The approach relies on TB-specific volatile organic compounds (VOCs) that are detected and quantified from the skin headspace. A specifically designed nanomaterial-based sensors array translates these findings into a point-of-care diagnosis by discriminating between active pulmonary TB patients and controls with sensitivity above 90%. This fulfills the WHO's triage test requirements and poses the potential to become a TB triage test.

Identifiants

pubmed: 34075714
doi: 10.1002/advs.202100235
pmc: PMC8336503
doi:

Substances chimiques

Biomarkers 0
Volatile Organic Compounds 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2100235

Subventions

Organisme : Ariane de Rothschild Foundation
Organisme : H2020 Industrial Leadership
ID : 824270
Organisme : Bill and Melinda Gates Foundation
ID : OPP1109493

Informations de copyright

© 2021 The Authors. Advanced Science published by Wiley-VCH GmbH.

Références

Tuberculosis (Edinb). 2012 Jul;92(4):314-20
pubmed: 22647661
Mol Cell. 2000 Apr;5(4):717-27
pubmed: 10882107
Nanomedicine. 2012 Jul;8(5):580-9
pubmed: 22033081
Environ Sci Technol. 2002 Oct 1;36(19):4121-6
pubmed: 12380084
Nanomedicine (Lond). 2014 Sep;9(13):1991-2002
pubmed: 25343349
Tuberculosis (Edinb). 2009 Jul;89(4):263-6
pubmed: 19481976
Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593
pubmed: 24448973
J Breath Res. 2014 Mar;8(1):014001
pubmed: 24421258
J Invest Dermatol. 2001 Apr;116(4):520-4
pubmed: 11286617
Adv Mater. 2018 Oct;30(41):e1705024
pubmed: 29498115
J Exp Med. 2005 Feb 21;201(4):535-43
pubmed: 15710652
Adv Sci (Weinh). 2021 Aug;8(15):e2100235
pubmed: 34075714
ACS Nano. 2021 Mar 23;15(3):3557-3567
pubmed: 33620208
PLoS One. 2013;8(2):e56074
pubmed: 23457502
Nat Rev Mol Cell Biol. 2001 Aug;2(8):569-77
pubmed: 11483990
Nat Nanotechnol. 2009 Oct;4(10):669-73
pubmed: 19809459
Curr Med Chem. 2007;14(9):987-95
pubmed: 17439398
Eur Respir J. 2014 May;43(5):1522-5
pubmed: 24789953
Xenobiotica. 1997 Jul;27(7):657-65
pubmed: 9253143
Adv Mater. 2021 Mar;33(11):e2004190
pubmed: 33533124
Chem Rev. 2019 Nov 27;119(22):11761-11817
pubmed: 31729868
Tuberculosis (Edinb). 2008 Jul;88(4):317-23
pubmed: 18296120
Br Med Bull. 2010;93:69-84
pubmed: 19926636
Anal Chem. 2011 Jul 15;83(14):5526-34
pubmed: 21619052
Chem Soc Rev. 2018 Jul 2;47(13):4781-4859
pubmed: 29888356
Afr J Lab Med. 2017 Mar 31;6(2):
pubmed: 28785533
J Clin Med. 2018 Oct 24;7(11):
pubmed: 30355982
ACS Nano. 2020 Sep 22;14(9):12125-12132
pubmed: 32808759
Analyst. 2008 Aug;133(8):1020-7
pubmed: 18645643
Adv Healthc Mater. 2016 Sep;5(18):2339-44
pubmed: 27390291
Br J Cancer. 2010 Aug 10;103(4):542-51
pubmed: 20648015
Toxicol In Vitro. 2005 Aug;19(5):685-93
pubmed: 15885978
Beilstein J Org Chem. 2012;8:290-9
pubmed: 22423297
Clin Biochem. 2013 Jan;46(1-2):40-4
pubmed: 23000316
ACS Nano. 2011 Aug 23;5(8):6743-53
pubmed: 21774511
Food Chem Toxicol. 2019 Aug;130 Suppl 1:110608
pubmed: 31238134
ACS Nano. 2017 Jan 24;11(1):112-125
pubmed: 28000444
J Chromatogr A. 2014 Jul 11;1350:1-9
pubmed: 24877978
Free Radic Biol Med. 1994 Aug;17(2):127-60
pubmed: 7959173
mBio. 2014 Feb 25;5(2):e00013-14
pubmed: 24570366
Environ Sci Technol. 1994 May 1;28(5):757-62
pubmed: 22191813
Adv Biosyst. 2019 Oct;3(10):e1900131
pubmed: 32648725
Environ Pollut. 2006 Mar;140(1):181-5
pubmed: 16125828
Lancet Infect Dis. 2003 May;3(5):288-96
pubmed: 12726978
Immunity. 2007 Sep;27(3):505-17
pubmed: 17892853
Small. 2009 May;5(10):1158-61
pubmed: 19274647
J Pharmacol Exp Ther. 1996 Jan;276(1):101-8
pubmed: 8558417
J Air Waste Manag Assoc. 2006 Nov;56(11):1503-17
pubmed: 17117735
iScience. 2019 Jan 25;11:178-188
pubmed: 30612036
Tuberculosis (Edinb). 2010 Mar;90(2):145-51
pubmed: 20189456
Infect Immun. 2012 Jun;80(6):1958-68
pubmed: 22431648
Appl Environ Microbiol. 1998 May;64(5):1715-20
pubmed: 9572941
Nanomedicine. 2013 Aug;9(6):758-66
pubmed: 23428987
Nanomedicine. 2014 Nov;10(8):1767-76
pubmed: 24954383
Adv Mater. 2018 Dec;30(50):e1802337
pubmed: 30073703
J Breath Res. 2010 Jun;4(2):026003
pubmed: 21383471
Nat Commun. 2019 Mar 8;10(1):1120
pubmed: 30850600
Nanomedicine (Lond). 2013 May;8(5):785-806
pubmed: 23656265
Chem Rev. 2008 Feb;108(2):705-25
pubmed: 18205411
J Crohns Colitis. 2015 Sep;9(9):731-7
pubmed: 26071410
Lancet Infect Dis. 2017 May;17(5):e144-e158
pubmed: 28291722
Respir Res. 2005 Jul 14;6:71
pubmed: 16018807
Tuberculosis (Edinb). 2012 Mar;92(2):182-6
pubmed: 22197664
ACS Sens. 2019 Oct 25;4(10):2588-2592
pubmed: 31613098
Clin Chim Acta. 2004 Sep;347(1-2):25-39
pubmed: 15313139
PLoS One. 2013;8(1):e54564
pubmed: 23358528
PLoS One. 2016 Oct 24;11(10):e0163388
pubmed: 27776140
PLoS One. 2010 Nov 04;5(11):e13813
pubmed: 21079799

Auteurs

Rotem Vishinkin (R)

Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.

Rami Busool (R)

Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.

Elias Mansour (E)

Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.

Falk Fish (F)

Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.

Ali Esmail (A)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town 7925, South Africa.

Parveen Kumar (P)

All India Institute of Medical Sciences, New Delhi, 110029, India.

Alaa Gharaa (A)

Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.

John C Cancilla (JC)

The Scintillon Institute, San Diego, CA, 92121, USA.

Jose S Torrecilla (JS)

Department of Chemical and Materials Engineering, Complutense University of Madrid, Madrid, 28040, Spain.

Girts Skenders (G)

Institute of Clinical and Preventive Medicine, University of Latvia and Riga east University Hospital, Riga, LV1079, Latvia.

Marcis Leja (M)

Institute of Clinical and Preventive Medicine, University of Latvia and Riga east University Hospital, Riga, LV1079, Latvia.

Keertan Dheda (K)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town 7925, South Africa.
Faculty of Infectious and Tropical Diseases, Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.

Sarman Singh (S)

All India Institute of Medical Sciences, New Delhi, 110029, India.

Hossam Haick (H)

Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, 3200003, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH